3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo- | 1348611-93-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo-
• 英文别名: 5-chloro-N-ethyl-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxoquinoline-3-carboxamide
• CAS: 1348611-93-7
• 化学式: C₁₉H₁₇ClN₂O₄
• 分子量: 372.8
• InChiKey: HBMNTNTZJMZXKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  4

ADMET

代谢

5-氯-N-乙基-4-羟基-N-(4-羟基苯基)-1-甲基-2-氧代-1,2-二氢喹啉-3-甲酰胺是拉喹尼莫德已知的人体代谢物。

5-chloro-N-ethyl-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide is a known human metabolite of laquinimod.

来源:NORMAN Suspect List Exchange

文献信息

• COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION
  申请人：Active Biotech AB

  公开号：EP3886858A1

  公开（公告）日：2021-10-06
• Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation
  申请人：Active Biotech AB

  公开号：US20210322400A1

  公开（公告）日：2021-10-21

  The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
• [EN] COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES OCULAIRES ASSOCIÉES À UNE VASCULARISATION EXCESSIVE
  申请人：ACTIVE BIOTECH AB

  公开号：WO2021123142A1

  公开（公告）日：2021-06-24

  The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age- related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.